| Clinically isolated syndrome
Copaxone vs Mayzent
Side-by-side clinical, coverage, and cost comparison for clinically isolated syndrome.Deep comparison between: Copaxone vs Mayzent with Prescriber.AI
AI compares prescribing info and payer-specific access barriers across 1,200+ formularies. Here's a preview of what prescribers are already asking.Safety signalsMayzent has a higher rate of injection site reactions vs Copaxone based on FDA-approved prescribing information
Coverage gaps3 major payers require step therapy for Mayzent but not Copaxone, including UnitedHealthcare
Sign up to reveal the full AI analysis
Category
Copaxone
Mayzent
At A Glance
SC injection
Daily or 3x weekly
Immunomodulator
Oral
Daily
S1P receptor modulator
Indications
- Clinically isolated syndrome
- Multiple Sclerosis, Relapsing-Remitting
- Multiple Sclerosis, Secondary Progressive
- Clinically isolated syndrome
- Multiple Sclerosis, Relapsing-Remitting
- active secondary progressive multiple sclerosis
Dosing
Clinically isolated syndrome, Multiple Sclerosis, Relapsing-Remitting, Multiple Sclerosis, Secondary Progressive 20 mg/mL SC once daily OR 40 mg/mL SC three times per week (at least 48 hours apart); the two strengths are not interchangeable.
Clinically isolated syndrome, Multiple Sclerosis, Relapsing-Remitting, active secondary progressive multiple sclerosis 2 mg orally once daily (CYP2C9 *1/*1, *1/*2, or *2/*2) or 1 mg orally once daily (CYP2C9 *1/*3 or *2/*3), each initiated with a dose titration regimen; administer tablets whole, do not split, crush, or chew.
Contraindications
- Known hypersensitivity to glatiramer acetate or mannitol, including anaphylaxis
- CYP2C9 *3/*3 genotype
- Myocardial infarction, unstable angina, stroke, TIA, decompensated heart failure requiring hospitalization, or Class III or IV heart failure within the last 6 months
- Mobitz type II second-degree, third-degree AV block, or sick sinus syndrome without a functioning pacemaker
Adverse Reactions
Most common (>=2%) Injection site erythema, pain, pruritus, mass, edema, and inflammation; vasodilatation, rash, dyspnea, chest pain, nausea, palpitations, lymphadenopathy, asthenia, anxiety, infection
Serious Anaphylactic reactions, immediate post-injection reaction, chest pain, lipoatrophy and skin necrosis, potential effects on immune response, hepatic injury
Postmarketing Sepsis, SLE syndrome, thrombosis, myocardial infarct, thrombocytopenia, lymphoma-like reaction, acute leukemia, cirrhosis, hepatic injury, anaphylactic reactions, cerebrovascular accident, pulmonary embolus, blindness
Most common (>=10%) headache, hypertension, transaminase increased
Serious infections, progressive multifocal leukoencephalopathy, macular edema, bradyarrhythmia and AV conduction delays, liver injury, cutaneous malignancies, posterior reversible encephalopathy syndrome, fetal risk
Postmarketing progressive multifocal leukoencephalopathy
Pharmacology
Glatiramer acetate is an immunomodulator thought to act by modifying immune processes responsible for MS pathogenesis; upon SC administration, glatiramer acetate-specific suppressor T-cells are induced and activated in the periphery.
Siponimod is an S1P receptor modulator that binds with high affinity to S1P receptors 1 and 5, blocking lymphocyte egress from lymph nodes and reducing peripheral blood lymphocyte counts; the therapeutic mechanism in multiple sclerosis is unknown but may involve reduction of lymphocyte migration into the central nervous system.
Enter your patient's insuranceCheck specific coverage details for your patient.
Most Common Insurance
Anthem BCBS
Copaxone
- Covered on 5 commercial plans
- PA (12/12) · Step Therapy (1/12) · Qty limit (11/12)
Mayzent
- Covered on 5 commercial plans
- PA (10/12) · Step Therapy (1/12) · Qty limit (9/12)
UnitedHealthcare
Copaxone
- Covered on 4 commercial plans
- PA (6/8) · Step Therapy (0/8) · Qty limit (7/8)
Mayzent
- Covered on 4 commercial plans
- PA (4/8) · Step Therapy (0/8) · Qty limit (4/8)
Humana
Copaxone
- Covered on 0 commercial plans
- PA (3/3) · Step Therapy (1/3) · Qty limit (3/3)
Mayzent
- Covered on 0 commercial plans
- PA (3/3) · Step Therapy (3/3) · Qty limit (3/3)
Coverage data sourced from MMIT. Updated monthly.
Savings
Cost estimate not availableAccessia Health: Multiple Sclerosis - Private Insurance: Waitlist
Commercial or private insurance
Medicare, Medicaid, VA, TRICARE
Cost estimate not availableAccessia Health: Multiple Sclerosis - Private Insurance: Waitlist
Commercial or private insurance
Medicare, Medicaid, VA, TRICARE
Compare Other Drugs
Let us handle your prior authsJust enter your patient's info and we'll:
- Verify eligibility with the payer.
- Pull the right PA forms directly from the payer.
- Submit, track & send live updates to your dashboard.
Free to start · HIPAA compliant
Next Steps for Your Patient
CopaxoneView full Copaxone profile
MayzentView full Mayzent profile
Clinical data sourced from FDA-approved labeling. Coverage data via MMIT. Updated monthly.